Lysogene EV/FCF

Mitä Lysogene tekee? Lysogene SA is a French biotech company founded in 2009. It specializes in researching and developing therapies for the treatment of rare genetic diseases caused by genetic mutations. Lysogene SA's business model is based on the development of gene therapies and biopharmaceuticals using adeno-associated viruses (AAV) and other technologies. Lysogene SA was founded out of the necessity to create urgently needed treatment options for patients with rare genetic diseases. The company was founded by a group of scientists, including the couple Karen Aiach and Olivier Danos. Karen Aiach, the CEO of Lysogene SA, saw her daughter suffer from a rare genetic disease called Sanfilippo syndrome and decided to do something to help other families going through the same thing. Since its founding, Lysogene SA has achieved several important milestones, including a successful IPO in 2017, listing the company on the Paris stock exchange Euronext. Lysogene SA offers a range of products and therapies based on AAV technology. AAVs are viral vectors that deliver genetic material to target cells and are used in the therapy of genetic diseases. AAV therapies are considered relatively safe and effective in the treatment of rare genetic diseases, as they enable long-lasting expression of therapeutic genes in target cells. Lysogene SA has several AAV-based therapies in various stages of clinical development, including LYSGENE693 for memory loss in Sanfilippo syndrome type A and B, as well as a program for the treatment of GM1 gangliosidosis, Gaucher disease, and Tay-Sachs syndrome. In addition to its AAV-based therapies, Lysogene SA also has a pipeline of biopharmaceuticals based on other technologies. These products are aimed at treating rare diseases such as metabolic disorders and neurodegenerative diseases. An example of this is the company's "Membrane Repair Enhancer" platform technology, which aims to promote the repair of cell membranes to alleviate the symptoms of various muscle diseases. Lysogene SA has also entered into a partnership with the pharmaceutical giant Sarepta Therapeutics to develop a gene therapy for the treatment of Duchenne muscular dystrophy (DMD), a degenerative muscle disease that begins in childhood and leads to the inability of children to walk or move. The partnership aims to combine Lysogene SA's AAV-based vector with Sarepta's DMD therapy to accelerate the path to clinical development and market approval. In summary, Lysogene SA is a biotech company focused on the development of gene therapies and biopharmaceuticals for the treatment of rare genetic diseases. The company has an impressive pipeline of products and partnerships focusing on various aspects of genetic disease therapy. With its innovative research and development, experienced team, and strong financial foundation, Lysogene SA is well-positioned to play a significant role in the development of therapies against rare genetic diseases. Lysogene on yksi Eurpooliin suosituimmista yhtiöistä.